Global Blood Therapeutics Inc. (NASDAQ:GBT) finished Wednesday with an addition of $0.63 to close at $32.00, an upside of 2.01 percent. An average of 1,200,920 shares of common stock have been traded in the last five days. There was a gain of $6.59 in the past week. The last 20 days have seen an average of 1,284,470 shares traded, while the 50-day average volume stands at 1,249,556.
GBT stock has increased by 21.72% in the last month. The company shares reached their 1-month lowest point of $25.11 on 10/01/21. With the stock rallying to its 52-week high on 01/27/21, shares of the company touched a low of $25.11 and a high of $63.65 in 52 weeks. In spite of this, the price is down -49.73% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
35 days have passed since Global Blood Therapeutics Inc. (GBT) last reported insider trading activity. Morrison Scott W, who is Director, most recently acquired $4,800 shares at $30.21 per share on Sep 09. In this transaction, the insider spent $145,003. Director, Svoronos Dawn, disposed of 1,609 shares at a price of $36.54 on Jun 18. The insider now owns more than $58,793 worth of shares. Prior to that, Director Pizzo Philip A. went on to Sale 1,065 shares at $36.54 each on Jun 18. An amount of $38,915 was transacted.
Global Blood Therapeutics Inc. (GBT) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 1.02. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 11.39, the price-to-book (PB) ratio at 6.31.
The quick ratio of Global Blood Therapeutics Inc. for the three months ended June 29 was 6.60, and the current ratio was 7.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.47 and a total debt to equity ratio of 0.47 for the quarter ending June 29. Global Blood Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -188.47%. Its gross profit as reported stood at $121.82 million compared to revenue of $123.8 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Global Blood Therapeutics Inc.’s return on assets was -39.70%, compared to -38.9% over the last five years. In the past year, the return on investment has been -43.00%, and the 5-year average is -43.3%. Meanwhile, the return on equity (ROE) for the past 12 months has been -68.60% and the 5-year average holds at -46.4%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Global Blood Therapeutics Inc. had $18.09 million in cash. The analyst consensus anticipated Global Blood Therapeutics Inc.’s latest quarter earnings to come in at -$1.19 per share, but it turned out to be -$1.12, a 5.90% surprise. For the quarter, EBITDA amounted to -$63.87 million. Shareholders own equity worth $62.41 million.
From a technical analysis perspective, let’s take a brief look at Global Blood Therapeutics Inc. (GBT) price momentum. RSI 9-day as of the close on 13 October was 77.62%, suggesting the stock is Overbought, with historical volatility in this time frame at 53.36%.
As of today, GBT’s price is $30.22 +25.93% or $6.59 from its 5-day moving average. GBT is currently trading +23.22% higher than its 20-day SMA and -15.34% lower than its 100-day SMA. However, the stock’s current price level is +19.00% above the SMA50 and -28.71% below the SMA200.
The stochastic %K and %D were 92.68% and 92.51%, respectively, and the average true range (ATR) was 1.49. With the 14-day stochastic at 93.54% and the average true range at 1.45, the RSI (14) stands at 68.48%. The stock has reached 2.93 on the 9-day MACD Oscillator while the 14-day reading was at 3.77.
Jefferies launched coverage on Global Blood Therapeutics Inc. (NASDAQ: GBT) in its analyst report released on October 07, 2021. The firm assigned the stock a a Buy rating.The consensus rating for Global Blood Therapeutics Inc. (GBT) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell GBT, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 16 others rate it as a “buy”.
What is GBT’s price target for the next 12 months?
Analysts predict a range of price targets between $30.00 and $138.00, with a median target of $73.50. Taking a look at these predictions, the average price target given by analysts for Global Blood Therapeutics Inc. (GBT) stock is $72.25.